247 related articles for article (PubMed ID: 17928010)
21. Proto-oncogene activation in liver tumors of hepatocarcinogenesis-resistant strains of mice.
Stanley LA; Devereux TR; Foley J; Lord PG; Maronpot RR; Orton TC; Anderson MW
Carcinogenesis; 1992 Dec; 13(12):2427-33. PubMed ID: 1361883
[TBL] [Abstract][Full Text] [Related]
22. Genotype-phenotype relationships in hepatocellular tumors from mice and man.
Stahl S; Ittrich C; Marx-Stoelting P; Köhle C; Altug-Teber O; Riess O; Bonin M; Jobst J; Kaiser S; Buchmann A; Schwarz M
Hepatology; 2005 Aug; 42(2):353-61. PubMed ID: 15965925
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of glutamine synthetase is associated with beta-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital.
Loeppen S; Schneider D; Gaunitz F; Gebhardt R; Kurek R; Buchmann A; Schwarz M
Cancer Res; 2002 Oct; 62(20):5685-8. PubMed ID: 12384525
[TBL] [Abstract][Full Text] [Related]
24. Hypomethylation of ras oncogenes in chemically induced and spontaneous B6C3F1 mouse liver tumors.
Vorce RL; Goodman JI
Mol Toxicol; 1989; 2(2):99-116. PubMed ID: 2702305
[TBL] [Abstract][Full Text] [Related]
25. Spontaneous and thiazolidinedione-induced B6C3F1 mouse hemangiosarcomas exhibit low ras oncogene mutation frequencies.
Duddy SK; Gorospe SM; Bleavins MR; de la Iglesia FA
Toxicol Appl Pharmacol; 1999 Oct; 160(2):133-40. PubMed ID: 10527912
[TBL] [Abstract][Full Text] [Related]
26. Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients.
Georgieva M; Krasteva M; Angelova E; Ralchev K; Dimitrov V; Bozhimirov S; Georgieva E; Berger MR
Oncol Rep; 2008 Jul; 20(1):3-11. PubMed ID: 18575712
[TBL] [Abstract][Full Text] [Related]
27. Frequent codon 12 Ki-ras mutations in mouse skin tumors initiated by N-methyl-N'-nitro-N-nitrosoguanidine and promoted by mezerein.
Rehman I; Lowry DT; Adams C; Abdel-Fattah R; Holly A; Yuspa SH; Hennings H
Mol Carcinog; 2000 Apr; 27(4):298-307. PubMed ID: 10747294
[TBL] [Abstract][Full Text] [Related]
28. Mutational analysis of the H-ras oncogene in spontaneous C57BL/6 x C3H/He mouse liver tumors and tumors induced with genotoxic and nongenotoxic hepatocarcinogens.
Fox TR; Schumann AM; Watanabe PG; Yano BL; Maher VM; McCormick JJ
Cancer Res; 1990 Jul; 50(13):4014-9. PubMed ID: 2191770
[TBL] [Abstract][Full Text] [Related]
29. Skin tumorigenesis and Ki-ras and Ha-ras mutations in tumors from adult mice exposed in utero to 3'-azido-2',3'-dideoxythymidine.
Zhang Z; Diwan BA; Anderson LM; Logsdon D; Olivero OA; Haines DC; Rice JM; Yuspa SH; Poirier MC
Mol Carcinog; 1998 Sep; 23(1):45-51. PubMed ID: 9766437
[TBL] [Abstract][Full Text] [Related]
30. Zonal gene expression in mouse liver resembles expression patterns of Ha-ras and beta-catenin mutated hepatomas.
Braeuning A; Ittrich C; Köhle C; Buchmann A; Schwarz M
Drug Metab Dispos; 2007 Apr; 35(4):503-7. PubMed ID: 17220236
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
[TBL] [Abstract][Full Text] [Related]
32. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
Bloethner S; Chen B; Hemminki K; Müller-Berghaus J; Ugurel S; Schadendorf D; Kumar R
Carcinogenesis; 2005 Jul; 26(7):1224-32. PubMed ID: 15760917
[TBL] [Abstract][Full Text] [Related]
33. Human p53 knock-in (hupki) mice do not differ in liver tumor response from their counterparts with murine p53.
Jaworski M; Hailfinger S; Buchmann A; Hergenhahn M; Hollstein M; Ittrich C; Schwarz M
Carcinogenesis; 2005 Oct; 26(10):1829-34. PubMed ID: 15917304
[TBL] [Abstract][Full Text] [Related]
34. Analysis of activated protooncogenes in B6C3F1 mouse liver tumors induced by ciprofibrate, a potent peroxisome proliferator.
Hegi ME; Fox TR; Belinsky SA; Devereux TR; Anderson MW
Carcinogenesis; 1993 Jan; 14(1):145-9. PubMed ID: 8425263
[TBL] [Abstract][Full Text] [Related]
35. Hypomethylation of ras oncogenes in chemically induced and spontaneous B6C3F1 mouse liver tumors.
Vorce RL; Goodman JI
J Toxicol Environ Health; 1991 Nov; 34(3):367-84. PubMed ID: 1658350
[TBL] [Abstract][Full Text] [Related]
36. Roles of the Pas1 and Par2 genes in determination of the unique, intermediate susceptibility of BALB/cByJ mice to urethane-induction of lung carcinogenesis: differential effects on tumor multiplicity, size and Kras2 mutations.
Karasaki H; Obata M; Ogawa K; Lee GH
Oncogene; 1997 Oct; 15(15):1833-40. PubMed ID: 9362450
[TBL] [Abstract][Full Text] [Related]
37. K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12.
Céspedes MV; Sancho FJ; Guerrero S; Parreño M; Casanova I; Pavón MA; Marcuello E; Trias M; Cascante M; Capellà G; Mangues R
Carcinogenesis; 2006 Nov; 27(11):2190-200. PubMed ID: 16679305
[TBL] [Abstract][Full Text] [Related]
38. Levels of 4-aminobiphenyl-induced somatic H-ras mutation in mouse liver DNA correlate with potential for liver tumor development.
Parsons BL; Beland FA; Von Tungeln LS; Delongchamp RR; Fu PP; Heflich RH
Mol Carcinog; 2005 Apr; 42(4):193-201. PubMed ID: 15761837
[TBL] [Abstract][Full Text] [Related]
39. Suppression of apoptosis in C3H mouse liver tumors by activated Ha-ras oncogene.
Frey S; Buchmann A; Bursch W; Schulte-Hermann R; Schwarz M
Carcinogenesis; 2000 Feb; 21(2):161-6. PubMed ID: 10657952
[TBL] [Abstract][Full Text] [Related]
40. Altered methylation of ras oncogenes in benzidine-induced B6C3F1 mouse liver tumors.
Vorce RL; Goodman JI
Toxicol Appl Pharmacol; 1989 Sep; 100(3):398-410. PubMed ID: 2551075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
